Alkermes expands the ALKS 7290 development program with the initiation of a Phase 2 study for the adjunctive treatment of major depressive disorder (MDD). Company announcement - FT.com.
Alkermes expands the ALKS 7290 development program with the initiation of a Phase 2 study for the adjunctive treatment of major depressive disorder (MDD). Company announcement - FT.com.
Want to see every report in real time?
Hundreds of sources worldwide, translated into your language, with alerts for what matters to you.
Sign up free Already have an account? Log in